Gene therapy for hemophilia B allowed almost three-fourths of patients to discontinue prophylactic factor IX therapy with no increase in bleeding, results of the pivotal BENEGENE-2 trial showed. The ...
Please provide your email address to receive an email when new articles are posted on . In this video, Iberia Romina Sosa, MD, PhD, discusses the results of a study presented at ASH Annual Meeting and ...
Cancers driven by hiccups in RNA processing can’t hide from our immune system, according to new work published today in Cell. A cross-institutional team Fred Hutch Cancer Center and Memorial Sloan ...
At a median follow-up of 3.5 years after gene therapy with a factor VIII–containing adeno-associated virus, 16 of 18 men with hemophilia A had enough factor VIII expression that bleeding events were ...
Testing and Interpretation of Human Epidermal Growth Factor Receptor 2 Protein Expression and ERBB2 Gene Amplification in Advanced Urothelial Carcinoma In total, 445 patients were sampled following a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results